New York, NY -- (SBWIRE) -- 12/27/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Vringo, Inc (NASDAQ:VRNG), Brigus Gold Corp (USA) (NYSEMKT:BRD), Peregrine Pharmaceuticals (NASDAQ:PPHM), Generex Biotechnology Corporation (OTCMKTS:GNBT)
Vringo, Inc (NASDAQ:VRNG) showed a volume of 1.06 million shares by the end of last trade whereas the average volume of the stock remained 1.15 million shares. The stock opened the session at $2.96 but then moved to $2.96. Vringo, Inc. (Vringo) is a development-stage company. The Company is engaged in developing software for mobile phones. It provides a platform, which allows users to create, download and share mobile entertainment content in the form of video ringtones for mobile phones. Vringo’s product consists of four components, such as The Vringo Mobile Application, The Vringo WAP Site, The Vringo Website and The Vringo Studio. Vringo (Israel) Ltd. is its wholly owned subsidiary. In July 2012, it merged with Innovate/Protect, Inc.
Will VRNG Continue To Move Higher? Find Out Here
Brigus Gold Corp (USA) (NYSEMKT:BRD) opened the session at $0.76 and closed the session at $00.795. The stock showed a positive performance of 2.83% in previous trading session. Brigus Gold Corp. (Brigus) is a mining company. The Company is engaged in the extraction, processing, and refining of gold deposits, as well as related activities, including the acquisition, exploration and development of mineral properties principally located in North America. Its sole mining operation is the Black Fox Mine. As of December 31, 2011, the Company was evaluating the Goldfields Project, which hosts the Box and Athona gold deposits.
For How Long BRD will fight for Profitability? Read This Trend Analysis report
Peregrine Pharmaceuticals (NASDAQ:PPHM) opened the session at $1.37 and closed the session at $1.37. The stock showed a negative performance of -1.44% in previous trading session. Traded with volume of 1.03 million shares in the prior session and the average volume of the stock remained 1.08 million shares. The beta of the stock remained 1.23. Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company developing monoclonal antibodies for the treatment and diagnosis of cancer. The Company's pipeline of investigational monoclonal antibodies is based on two technology platforms, including PS-targeting antibodies and DNA/histone-targeting antibodies. Bavituximab is the Company's therapeutic PS-targeting antibody, which has demonstrated therapeutic potential and represents a new approach to treating cancer. PGN650 is the Company's PS-targeting imaging agent that represents a potential new approach to imaging cancer.
Why Should Investors Buy PPHM After the Recent Fall? Just Go Here and Find Out
Generex Biotechnology Corporation (OTCMKTS:GNBT) the stock advanced 1.75% and finished the session at $0.0290. Traded with volume of 1.03 million shares in the prior session and the average volume of the stock remained 1.89 million shares. The beta of the stock remained 2.13. Generex Biotechnology Corporation is a Canada-based Company, which develops drug delivery systems and technologies for the treatment of diabetes. The Company has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity. Its buccal insulin spray product, Generex Oral-lyn is in Phase III clinical trials at several sites around the world.
Will GNBT Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)